Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolaj Frost

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Plos Genetics|June 28, 2008
Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgammaAnna Foryst-Ludwig, Markus Clemenz, Stephan Hohmann, et al.
Clinical Lung Cancer|March 2, 2021
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and SteroidsNikolaj Frost, Jens Kollmeier, Daniel Misch, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
Independent Validation of a Machine Learning Classifier for Predicting Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer Using Routinely Obtainable [<sup>18</sup>F]FDG-PET/CT ParametersAgata Wdowiak, Julian M M Rogasch, Georg L Baumgärtner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2023
A machine learning tool to improve prediction of mediastinal lymph node metastases in non-small cell lung cancer using routinely obtainable [<sup>18</sup>F]FDG-PET/CT parametersJulian M M Rogasch, Liza Michaels, Georg L Baumgärtner, et al.
Lung Cancer (Amsterdam, Netherlands)|October 22, 2019
Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic optionsPhilipp Jurmeister, Claudia Vollbrecht, Anke Behnke, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2021
FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflowJulian M M Rogasch, Nikolaj Frost, Stephanie Bluemel, et al.
BMC Health Services Research|July 3, 2025
Recruiting patients into a healthcare services trial: lessons learned from a feasibility study to investigate a patient-oriented navigation intervention for age-associated diseasesKathrin Gödde, Hella Fügemann, Ulrike Grittner, et al.
JAMA Network Open|April 29, 2022
Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non-Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical ResectionDavid Wasilewski, Josefine Radke, Ran Xu, et al.
Current Medical Research and Opinion|September 1, 2022
Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIRChristian Geßner, Thomas Fietz, Christoph Losem, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysisJan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Plos Genetics|June 28, 2008
Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgammaAnna Foryst-Ludwig, Markus Clemenz, Stephan Hohmann, et al.
Clinical Lung Cancer|March 2, 2021
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and SteroidsNikolaj Frost, Jens Kollmeier, Daniel Misch, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
Independent Validation of a Machine Learning Classifier for Predicting Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer Using Routinely Obtainable [<sup>18</sup>F]FDG-PET/CT ParametersAgata Wdowiak, Julian M M Rogasch, Georg L Baumgärtner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2023
A machine learning tool to improve prediction of mediastinal lymph node metastases in non-small cell lung cancer using routinely obtainable [<sup>18</sup>F]FDG-PET/CT parametersJulian M M Rogasch, Liza Michaels, Georg L Baumgärtner, et al.
Lung Cancer (Amsterdam, Netherlands)|October 22, 2019
Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic optionsPhilipp Jurmeister, Claudia Vollbrecht, Anke Behnke, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2021
FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflowJulian M M Rogasch, Nikolaj Frost, Stephanie Bluemel, et al.
BMC Health Services Research|July 3, 2025
Recruiting patients into a healthcare services trial: lessons learned from a feasibility study to investigate a patient-oriented navigation intervention for age-associated diseasesKathrin Gödde, Hella Fügemann, Ulrike Grittner, et al.
JAMA Network Open|April 29, 2022
Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non-Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical ResectionDavid Wasilewski, Josefine Radke, Ran Xu, et al.
Current Medical Research and Opinion|September 1, 2022
Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIRChristian Geßner, Thomas Fietz, Christoph Losem, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysisJan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
Pageof 7